Nihon Chouzai Co

Nihon Chouzai Co EBITDA per Employee

Delisted

The EBITDA per Employee of Nihon Chouzai Co (3341.T) as of Oct 29, 2026 is 1.42 M JPY. In the previous year, EBITDA per Employee was 2.09 M JPY — a change of -31.75% (lower).

EBITDA per Employee

1.42 MJPY

YoY

-31.75%

Last updated:

EBITDA per Employee of Nihon Chouzai Co is 2025 1.42 M JPY. EBITDA per Employee of Nihon Chouzai Co was 2024 2.09 M JPY. It decreases by -31.75% lower compared to the previous year.

The Nihon Chouzai Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
2.42 M JPY
Jan 1, 2019
1.54 M JPY
Jan 1, 2020
1.73 M JPY
Jan 1, 2021
3.35 M JPY
Jan 1, 2022
3.04 M JPY
Jan 1, 2023
3.30 M JPY
Jan 1, 2024
2.09 M JPY
Jan 1, 2025
1.42 M JPY
The Nihon Chouzai Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
1.42 MJPY-31.75%
2.09 MJPY-36.74%
3.30 MJPY+8.54%
3.04 MJPY-9.27%
3.35 MJPY+93.28%
1.73 MJPY+12.77%
1.54 MJPY-36.40%
2.42 MJPY+24.28%
1.94 MJPY-18.78%
2.39 MJPY+57.80%
1.52 MJPY+40.11%
1.08 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nihon Chouzai Co Stock analysis

What does Nihon Chouzai Co do? Nihon Chouzai Co Ltd is a Japanese pharmaceutical company that was founded in 1970. It specializes in the development and sale of pharmaceutical products and has built an impressive track record in recent decades. The business model of Nihon Chouzai is based on the manufacturing and sale of high-quality drugs for various diseases such as diabetes, hypertension, cardiovascular diseases, and cancer treatments. In addition, the company also offers a wide range of medical devices such as blood pressure monitors and insulin pens for diabetics. Another important division of Nihon Chouzai is the provision of pharmacy services to individual customers. The history of Nihon Chouzai began in the 1970s when the Japanese government launched a campaign to promote healthcare. The company recognized the importance of this campaign and started manufacturing quality drugs that were affordable for the general population. Since then, Nihon Chouzai has continuously invested in research and development to improve disease treatment. The company has also formed partnerships with other leading pharmaceutical companies worldwide to develop new medical technologies and treatment methods. In recent years, Nihon Chouzai has also conducted a number of acquisitions and mergers to expand its business. One of the most significant acquisitions was the acquisition of Daiichi Sankyo, a leading Japanese pharmaceutical company. In terms of products, Nihon Chouzai offers a wide range of drugs that cater to the needs of different patient groups. These include innovative cancer therapies, diabetes medications, lipid-lowering drugs, and blood pressure medications. Nihon Chouzai is also a leading provider of medical devices and consumables. The key products in this area are blood glucose monitors for diabetics, acupuncture needles for pain relief, and optical fiber endoscopic devices for gastroenterology. In addition to its consumer product offerings, Nihon Chouzai also provides specialized pharmacy services to individual customers. These services include setting up remote pharmacies for rural areas, conducting training for pharmacy technicians, and providing medical expertise to the public. Overall, Nihon Chouzai has established itself as a successful pharmaceutical and medical technology company that operates both in Japan and globally. The company relies on innovative research and development to meet the expectations of patients and doctors and improve healthcare. Nihon Chouzai Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nihon Chouzai Co stock

EBITDA per Employee of Nihon Chouzai Co is 1.42 M JPY in 2025.

EBITDA per Employee of Nihon Chouzai Co changed from 2.09 M JPY to 1.42 M JPY, representing a -31.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Nihon Chouzai Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Nihon Chouzai Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Nihon Chouzai Co

All Key Metrics — Nihon Chouzai Co